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those with traumatic injury in a multi-payer US population.
Increasing severity appears to increase the likelihood of develop-
ing a DVT. Further, new interventions that mitigate the develop-
ment of DVT may reduce the economic burden of traumatic
injury among pediatric hospitalizations. Clinicians and other
decision makers should be aware of the relationship between
injury severity and DVT development and resource utilization-
associated outcomes.
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OBJECTIVE: Medications used to control DM2 and hyperten-
sion are common associated with ED problems. This had affected
adherence and therefore the long-term control of Mexican
patients with those diseases, increasing long-term complications
and health care costs. The purpose of the study was to evaluate
the cost-effectiveness of using ED treatments as adjuvant thera-
pies in patients with DM2 and hypertension from an institutional
perspective. METHODS: A cost-effectiveness assessment was
performed employing a ten-years decision tree model. Compara-
tors used in the model were Sildenaﬁl (50 mg/day-100 mg/day);
Taladaﬁl (20 mg/day) and Vardenaﬁl (10 mg/day-20 mg/day).
Effectiveness measure used was the number of hospitalization
avoided related to uncontrolled-patients due to ED causes. The
transition probabilities were obtained from international pub-
lished literature and a local survey, previously validated, related
to ED problems in Mexican patients(n = 146 with DM2; n = 326
with hypertension) at multiple second-level Hospitals within the
Social Security Mexican Institute (IMSS). Resource use data was
obtained from hospital records(n = 1000) and a 3% discount
rate was used. The model was calibrated according to interna-
tional guidelines. Probabilistic sensitivity analyses were per-
formed using bootstrapping techniques. RESULTS: Savings per
patient with DM2 were US$816.70 for sildenaﬁl 50 mg/day;
US$668.30 for sildenaﬁl 100 mg/day; US$711.20 for tadalaﬁl;
US$646.30 for vardenaﬁl 10 mg/day and US$603.50 for vard-
enaﬁl 20 mg/day. Annual mean savings per patient with hyper-
tension resulted in US$1627.00; US$1447.50, US$1520.80,
US$1444.50 and US$1432.20; respectively following the order
above. Patients treated with ED therapies avoided signiﬁcant
number of hospitalizations (complications) in both diseases and
sildenaﬁl 50 mg/day was the therapy which showed the higher
number of hospitalizations avoided(23 for DM2 and 25 for
hypertension). ICER’s showed Sildenaﬁl 50 mg/day as the domi-
nant treatment. The results were robust to probabilistic sensi-
tivity analyses and acceptability curves. CONCLUSION: ED
therapies should be employed in males who show this pro-
blem secondary to DM2 and hypertension. These results could be
used by Mexican decision-makers to generate cost-containment
strategies.
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OBJECTIVE: High blood pressure is common in menopausal
women and some hormone therapies (HT) for menopause may
contribute to increased blood pressure. However, the burden of
illness (BOI) of hypertension in women receiving menopausal HT
is not well-documented in the current literature. This study esti-
mates the prevalence and economic burden of hypertension in
this patient population. METHODS: Patients with at least one
prescription for menopausal HT were selected from the Phar-
Metrics database during the period from July 1, 2003–June 30,
2005. HT patients were divided into those with and without
hypertension. The non-hypertensive cohort was propensity score
matched to the hypertensive cohort, controlling for patient
demographics, overall comorbidities, and type of HT use. The
BOI of hypertension was deﬁned as the difference in average
annual total health care expenditures per person between the
cohorts. RESULTS: The prevalence of menopausal HT use was
9.75% among potentially eligible patients in this commercially-
insured sample. Hypertension was the most common comorbid-
ity, with a prevalence of 34%. HT patients with hypertension
(n = 106,729) had signiﬁcantly higher average annual health
care expenditures compared with matched HT patients without
hypertension ($8,908 versus $5,960; difference of $2,948;
P < 0.001). Less than 1% was due to differences in menopause-
related care between the cohorts; 54% was attributable to
hypertension-related care and 45% to the care of other common
comorbidities, such as lipid disorders. CONCLUSION: Hyper-
tension is the most common comorbidity among commercially-
insured menopausal hormone therapy users in the United States.
The annual incremental BOI of hypertension among HT users is
both substantial and statistically signiﬁcant, averaging $2,948
per patient per year. Given the number of menopausal women
who use HT and the prevalence of hypertension in this cohort,
employers and medical care payers should be interested in ﬁnding
ways to lessen the burden associated with hypertension.
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OBJECTIVE: In Ukraine the State program «Reproductive
health of the nation for the period till 2015», providing reduction
in the quantity of abortions is authorized, using hormonal con-
traception. The aim was to identify the most cost-effective oral
or transdermal contraceptives using a provider perspective.
METHODS: A decision tree was developed to compare the cost-
effectiveness of oral contraceptive 3 mg drospirenone/0.03 mg
ethinylestradiol (D-E) vs. 0.25 mg norgestimate/0.035 mg
ethynilestradiol (NA-E) vs. transdermal contraceptive 6 mg
norelgestromin/0.6 mg ethynilestradiol (transdermal N-E) for
preventing a pregnancy per patient per year. Direct medical
cost were based on average wholesale prices for medicines
(01.10.2007), ans physician, laboratory costs based on tariffs of
Lviv family planning center. Probability data that included com-
pliance and pregnancy rates were extracted from randomized
clinical trials and public resources. A probablistic sensitivity
analysis of free parameters was conducted through a Monte-
Carlo simulation. Key parameters were sampled from beta
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disributions. RESULTS: In the base case, NA-E was found to be
the most cost-effective alternative. NA-E cost 321UAH (1
USD = 5.05 UAH) compared to 930UAH for D-E, 1319UAH for
transdermal N-E to prevent a single pregnancy per patient per
year. Monte –Carlo sensivity analysis conﬁrmed these ﬁndings.
CONCLUSION: The cost-effectiveness ratio NA-E dominated
all contraceptive strategies.These direct medical costs, in turn,
were driven by differential compliance that favored NA-E.
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OBJECTIVE: To conduct a cost-effectiveness analysis of contra-
ceptives available in the United States from a payer’s perspective.
METHODS: A Markov model was constructed to simulate
method failure (deﬁned as ectopic pregnancy, abortion, or full-
term birth) and costs among 17 contraceptive methods over a
5-year period: vasectomy, tubal ligation, injectable, implant,
copper-T IUD, LNG-20 IUS, oral contraceptives, diaphragm,
male condom, female condom, spermicides, sponge, patch,
NuvaRing, withdrawal, periodic abstinence and no method. In
each yearly cycle, subjects transition to “continue contracep-
tion”, “method failure” or “plan disenrollment”. Subjects
remain on the method for the model duration after method
failure or adverse effect. We assumed that 60% of unintended
births are mistimed and would occur two years later. Failure rate,
adverse event rates, and resource utilization were derived from
comprehensive literature review and supplemented with expert
opinion. Unit costs were obtained from published fee schedules
and drug prices. Future costs and effectiveness were discounted at
3%/year. Sensitivity analyses were performed on cost and failure
rates. RESULTS: Any contraceptive method is superior to “no
method” in terms of costs and success rate. The three least
expensive methods were copper-T IUD ($645), vasectomy ($713)
and LNG-20 IUS ($930). The most effective methods (99.6%
success rate) were vasectomy, implant, tubal ligation, LNG-20
IUS and copper-T IUD. Results were sensitive to variations in
cost of contraception method, cost of unintended pregnancy and
plan disenrollment rates. Moreover, with a longer time horizon,
methods with high initial costs (ie, copper-T IUD, vasectomy
and LNG-20 IUS) and high effectiveness rates become more
cost-effective. CONCLUSION: Copper-T IUD, vasectomy and
LNG-20 IUS are among the most effective methods currently
available in the US market. This analysis demonstrates that dif-
ferences in efﬁcacy, method costs, cost of unintended pregnancies
and time horizon are inﬂuential factors that determine the overall
value of a contraception method.
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OBJECTIVE: To estimate the cost-effectiveness of screening
for vasa previa at 18–20 weeks gestation. Several screening
strategies were considered for singleton and twin pregnancies.
METHODS: We constructed a decision-analytic model to esti-
mate the incremental costs and beneﬁts associated with screening
for vasa previa at 18–20 weeks gestation. We compared the
status quo of not screening to scenarios in which all singleton and
twin pregnancies were screened using transvaginal color Doppler
ultrasound. We also considered strategies in which only high-risk
pregnancies were screened. Costs were collected primarily from
the London Health Sciences Centre case costing initiative and
from the OHIP Schedule of Beneﬁts for Physicians. Other data
estimates were obtained from published sources and expert
opinion. Health beneﬁts were measured in life-years (LY) gained.
Costs and health beneﬁts were estimated for a cohort of preg-
nancies in Ontario in 1 year. RESULTS: Compared to not screen-
ing, screening all twin pregnancies for vasa previa has an
incremental cost effectiveness ratio (ICER) of less than $10,000
per LY gained. Among all risk factors in singleton pregnancies,
velementous cord insertion is the strongest predictor of vasa
previa. Identifying and screening pregnancies affected by vela-
mentous cord insertion has an ICER of less than $10,000 per LY
gained compared to not screening. Compared to screening only
pregnancies identiﬁed as having a velamentous cord insertion,
screening all pregnancies has an ICER of approximately $75,000
per LY-gained. Compared to screening for vasa previa in
pregnancies identiﬁed as having any high risk indicator, routine
screening of all pregnancies has an ICER of over $100,000 per
LY gained. CONCLUSION: A strategy of screening all twin and
all high-risk singleton pregnancies for vasa previa has a very low
incremental cost effectiveness ratio and should be considered for
adoption. However, routine screening of all pregnancies is not
likely to be cost effective.
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OBJECTIVE: Prophylactic therapy with palivizumab, a human-
ized monoclonal antibody, reduces the number of respiratory
syncytial virus (RSV)-related hospitalizations in preterm infants,
including those in the 32 to 35 weeks gestational age (GA)
subgroup. The cost-effectiveness of this therapy in Canada is
unknown. To evaluate the cost-effectiveness of palivizumab as
respiratory syncytial virus prophylaxis in premature infants born
at 32 to 35 weeks GA, from both the payer (base-case) and
societal perspectives. METHODS: A decision analytic model was
designed to compare costs and beneﬁts of prophylaxis in this
subgroup of premature infants. Sensitivity analyses were per-
formed to ascertain the robustness of the model by varying
mortality, health utilities, discount rates and administration
costs. SETTING: Canadian publicly funded health care system
(base-case analysis). PARTICIPANTS: Canadian infants born at
32 to 35 weeks gestation without chronic lung disease. INTER-
VENTIONS: Palivizumab prophylaxis versus no prophylaxis.
MAIN OUTCOME MEASURES: Expected costs and incremen-
tal cost-effectiveness ratio expressed as cost per quality-adjusted
life-year (QALY) gained using $CAN 2006. RESULTS: The
expected costs were higher for palivizumab prophylaxis as com-
pared with no prophylaxis. The incremental cost-effectiveness
ratio for the base-case scenario was $16,605 per QALY after
discounting, which is considered cost-effective. Sensitivity analy-
ses showed the model was robust through reasonable estimates
of key variables. Sub-analyses that varied risk of RSV based on
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